Millipore Sigma Vibrant Logo

407240 Insulin-Like Growth Factor-I, Human, Recombinant, E. coli

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: rhIGF-I, Somatomedin-C

407240
  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Spec Table

      Purity
      ≥97% by SDS-PAGE
      Description
      Overview

      This product has been discontinued.





      Recombinant, human insulin-like growth factor-I (70 amino acids) expressed in E. coli. Has about 40% homology to insulin and produces metabolic effects similar to insulin. Acts as an important local regulator of bone formation. Increases bone formation and bone resorption. Also inhibits etoposide-induced apoptosis in BALB/c 3T3 cells. Stimulates the activity of protein tyrosine kinases in both normal and diethylstilbestrol-treated hamster kidneys. Primarily involved in response of cells to growth hormones.
      Catalogue Number407240
      Brand Family Calbiochem®
      SynonymsrhIGF-I, Somatomedin-C
      References
      ReferencesStabnov, L., et al. 2002. Bone 30, 909.
      Devireddy, L.R., et al. 2001. Science 293, 829.
      Chen, C.W., and Ray, D. 1995. Carcinogenesis 16, 1339.
      Sell, C., et al. 1995. Cancer Res. 55, 303.
      Amarani, S., et al. 1993. J. Bone Min. Res. 8, 157.
      Mohan, S. 1993. Growth Regul. 3, 67.
      Lowe, W.L. 1991. In Insulin-Like Growth Factors: Molecular and Cellular Aspects (LeRoith, D., ed.) CRC Press Inc. Boca Raton, FL. p. 49.
      Rudd, B.T. 1991. Ann. Clin. Biochem. 28, 542.
      Schofield, P.N. 1991. Acta Paediatr. Scand. 372, 83.
      Werner, H., et al. 1991. In Molecular Biology and Physiology of Insulin and Insulin-Like Growth Factors (Raizada, M.K., and LeRoith, D., eds.) Plenum, NY. p. 263.
      Humbel, R.E. 1984. In Hormonal Proteins and Peptides (Jin Li, C.H., ed.) Academic, NY. Vol. 12, p. 57.
      Product Information
      CAS number67763-96-6
      FormLyophilized
      Applications
      Biological Information
      Biological activityED₅₀ = 0.3-1.5 ng/ml as measured in a cell proliferation assay with MCF-7 human breast carcinoma cells.
      Purity≥97% by SDS-PAGE
      Physicochemical Information
      ContaminantsEndotoxin: ≤1 EU/µg IGF-I
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSNM8905000
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Avoid freeze/thaw cycles of solutions. Stock solutions are stable for up to 3 months at -70°C. Dilute with buffer to desired pH just prior to use.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      407240 0

      Documentation

      Insulin-Like Growth Factor-I, Human, Recombinant, E. coli SDS

      Title

      Safety Data Sheet (SDS) 

      Insulin-Like Growth Factor-I, Human, Recombinant, E. coli Certificates of Analysis

      TitleLot Number
      407240

      References

      Reference overview
      Stabnov, L., et al. 2002. Bone 30, 909.
      Devireddy, L.R., et al. 2001. Science 293, 829.
      Chen, C.W., and Ray, D. 1995. Carcinogenesis 16, 1339.
      Sell, C., et al. 1995. Cancer Res. 55, 303.
      Amarani, S., et al. 1993. J. Bone Min. Res. 8, 157.
      Mohan, S. 1993. Growth Regul. 3, 67.
      Lowe, W.L. 1991. In Insulin-Like Growth Factors: Molecular and Cellular Aspects (LeRoith, D., ed.) CRC Press Inc. Boca Raton, FL. p. 49.
      Rudd, B.T. 1991. Ann. Clin. Biochem. 28, 542.
      Schofield, P.N. 1991. Acta Paediatr. Scand. 372, 83.
      Werner, H., et al. 1991. In Molecular Biology and Physiology of Insulin and Insulin-Like Growth Factors (Raizada, M.K., and LeRoith, D., eds.) Plenum, NY. p. 263.
      Humbel, R.E. 1984. In Hormonal Proteins and Peptides (Jin Li, C.H., ed.) Academic, NY. Vol. 12, p. 57.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision31-March-2008 JSW
      SynonymsrhIGF-I, Somatomedin-C
      DescriptionRecombinant, human insulin-like growth factor-I (70 amino acids) expressed in E. coli. Growth-promoting, single-chain polypeptide hormone that is structurally, functionally, and genetically related to insulin. Has about 40% homology to insulin and produces metabolic effects similar to insulin. Functionally, the IGFs share three activities with insulin: demonstrate insulin-like metabolic activity, induce sulfate uptake into cartilage proteoglycans, and induce mitotic activity in selected cell lines. Acts as an important local regulator of bone formation. Also inhibits etoposide-induced apoptosis in BALB/c 3T3 cells.
      FormLyophilized
      CAS number67763-96-6
      RTECSNM8905000
      Purity≥97% by SDS-PAGE
      ContaminantsEndotoxin: ≤1 EU/µg IGF-I
      Biological activityED₅₀ = 0.3-1.5 ng/ml as measured in a cell proliferation assay with MCF-7 human breast carcinoma cells.
      SolubilityReconstitute to ≥0.1 mg/ml with sterile PBS containing 0.1% BSA or HSA.
      Storage ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Avoid freeze/thaw cycles of solutions. Stock solutions are stable for up to 3 months at -70°C. Dilute with buffer to desired pH just prior to use.
      Toxicity Standard Handling
      Merck USA index14, 4986
      ReferencesStabnov, L., et al. 2002. Bone 30, 909.
      Devireddy, L.R., et al. 2001. Science 293, 829.
      Chen, C.W., and Ray, D. 1995. Carcinogenesis 16, 1339.
      Sell, C., et al. 1995. Cancer Res. 55, 303.
      Amarani, S., et al. 1993. J. Bone Min. Res. 8, 157.
      Mohan, S. 1993. Growth Regul. 3, 67.
      Lowe, W.L. 1991. In Insulin-Like Growth Factors: Molecular and Cellular Aspects (LeRoith, D., ed.) CRC Press Inc. Boca Raton, FL. p. 49.
      Rudd, B.T. 1991. Ann. Clin. Biochem. 28, 542.
      Schofield, P.N. 1991. Acta Paediatr. Scand. 372, 83.
      Werner, H., et al. 1991. In Molecular Biology and Physiology of Insulin and Insulin-Like Growth Factors (Raizada, M.K., and LeRoith, D., eds.) Plenum, NY. p. 263.
      Humbel, R.E. 1984. In Hormonal Proteins and Peptides (Jin Li, C.H., ed.) Academic, NY. Vol. 12, p. 57.

      Related Products & Applications

      Related Products

      Catalogue Number Description  
      407245 Insulin-Like Growth Factor-II, Human, Recombinant, E. coli Show Pricing & Availability

      Categories

      Life Science Research > Proteins and Enzymes > Cytokines & Growth Factors
      Life Science Research > Cell Culture and Systems > Cell Culture Media and Supplements > Cell Culture Supplements > Cytokines & Growth Factors